GDRX Price Prediction Next Week
Analysis and Insights
News Impact Analysis:
CFO Resignation: The sudden resignation of CFO Karsten Voermann has led to a 7% drop in GDRX stock price, indicating investor concern about leadership stability and upcoming financial results.
Analyst Ratings: Despite the resignation, Leerink Partners maintains a Buy rating with a $10 price target, citing stability under the new CEO and positive growth prospects.
Q4 Results: GDRX reported mixed Q4 results with revenue slightly below expectations but showed strength in Pharma manufacturer solutions.
Technical Analysis:
- Current Price: $4.64 to $4.65
- RSI: 48 (Neutral)
- MACD: Slightly negative, indicating bearish momentum
- Fibonacci Levels: Resistance at $4.85 and $5.00; Support at $4.37 and $4.22
Price Prediction and Recommendation:
Based on the news impact and technical indicators, GDRX is expected to face selling pressure in the next trading week. The stock may test the lower support levels.
Predicted Price: $4.20
Recommendation: Sell or avoid buying at current levels due to potential downward pressure.
GDRX Similar Chart Price Prediction
The price of GDRX is predicted to go up 0.52%, based on the high correlation periods with FAF. The similarity of these two price pattern on the periods is 92.35%.
GDRX
FAF
Up: 0.52%Similarity: 92.35%
GDRX Revenue Forecast
GDRX EPS Forecast
GDRX FAQs
What is GDRX revenue forecast for next quarter？
GDRX Analyst's Forecast
Daniel Grosslight
Citigroup
Strong Buy
2025-01-10
Price Target
$7 → $6.25
Upside
+37.36%
Citi analyst Daniel Grosslight lowered the firm's price target on GoodRx to $6.25 from $7 and keeps a Buy rating on the shares as part of a 2025 outcook for the health technology and distribution group. The firm says that while 2024 was another difficult year for health tech stocks, rather than being driven by deteriorating fundamentals, much of the selloff was due to continued multiple compression, which signals "we have likely reached a valuation floor." Looking ahead to 2025, Citi is "cautiously optimistic" on the health tech space, saying there seems to be a bit of a post-election risk bid, acquisition activity has accelerated, and expectations have been sufficiently reset. Citi names Health Catalyst (HCAT) its top health tech pick and Cencora (COR) its top distribution pick.
Scott Schoenhaus
Keybanc
Buy
2025-01-08
Price Target
$7 → $6
Upside
+40.19%
Craig Hettenbach
Morgan Stanley
Hold
2024-12-17
Price Target
$7 → $6
Upside
+34.53%
